Chadi Nabhan, hematologist and medical oncologist, Chief Medical Officer and Head of Strategy at Ryght, shared on LinkedIn:
“Menin inhibitors are reshaping the treatment of AML.
In the KOMET-007 trial, the menin inhibitor ziftomenib was added to intensive induction chemotherapy for patients with NPM1-mutated AML.
On the latest Healthcare Unfiltered EXPRESS, I sit down with Amer Zeidan to discuss the rationale, results, safety, and unanswered questions surrounding KOMET-007 and what these data may mean for the future of AML treatment.
For patients with AML, progress cannot come quickly enough.
Studies like KOMET-007 offer genuine reason for optimism.
Check out the podcast, share, subscribe, and join the conversation.”
YouTube
Apple Podcasts
Spotify
Other articles about Acute Myeloid Leukemia on OncoDaily.